Italian Study on Depressive Disorders (STudio Italiano MAlattia Depressiva, or STIMA-D): A Nationwide Snapshot of the Status of Treatment for Major Depression

Abstract

Introduction: Major depression is a worldwide problem and often remains undetected and untreated. Given the low rates of detection plus the need to intervene in a short time, it is important to identify factors which are likely to improve treatment outcomes.

Methods: STIMA-D was designed to provide the profile of patients with major depression in Italy (focusing on pathway to care, patient characteristics, drug therapy and treatment outcomes). The patients enrolled (M/F, aged between 18 and 65) experienced single/multiple episodes of major depression (DSM-IV-TR). Patients with lifetime or current bipolar syndrome or other mental disorders were excluded.

Results: 44 of the 50 invited centers sent data concerning 1 140 patients. The majority of patients were women. Among working individuals, 52.5% of them were absent from work due to depression in the previous 6 months. Recurrent episodes of major depression were very common and were associated with persistence of residual post-episodic symptoms, a family history of mood disorders and presence of anxiety. 59.6% of the patients were treated with monotherapy (SSRI or SNRI), while 19.2% of them were treated with SSRI plus SNRI. Only the 25.5% on monotherapy had a complete response compared to 12.4% of patients on dual therapy.

Discussion: Poor outcomes in major depression have profound implications on patients’ quality of life and cost burden. New pharmacological approaches with novel modes of action are therefore urgently needed.

Key words

major depression - antidepressants - relapse - side-effects

• References

• 1 The World Health Organization . The global burden of disease. 2004 update. Table A2: Burden of disease in DALYs by cause, sex and income group in WHO regions, estimates for 2004. Geneva, Switzerland: WHO; 2008. http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf
• 2 De Girolamo G, Polidori G, Morosini P et al. La prevalenza dei disturbi mentali in Italia. Il progetto ESEMeD-WMH. Epidemiol Psichiatr Soc 2005; 14: 1-100
• 3 Waraich P, Goldner EM, Somers JM et al. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatry 2004; 49: 124-138
• 4 Fournier JC, DeRubeis RJ, Hollon SD et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303: 47-53
• 5 Singleton N, Bumpstead R, O’Brien M et al. Psychiatric morbidity among adults living in private households, 2000. Int Rev Psychiatry 2003; 15: 65-73
• 6 Coyne JC, Schwenk TL, Fechner-Bates S. Nondetection of depression by primary care physicians reconsidered. Gen Hosp Psychiatry 1995; 17: 3-12
• 7 Tiemens BG, Ormel J, Simon GE. Occurrence, recognition, and outcome of psychological disorders in primary care. Am J Psychiatry 1996; 153: 636-644
• 8 Simon GE, Goldberg D, Tiemens BG et al. Outcomes of recognized and unrecognized depression in an international primary care study. Gen Hosp Psychiatry 1999; 21: 97-105
• 9 Egede LE. Failure to recognize depression in primary care: issues and challenges. J Gen Intern Med 2007; 22: 701-703
• 10 Goldberg D, Huxley P. Mental Illness in the Community: The Pathway to Psychiatric Care. London: Tavistock; 1980
• 11 Saver BG, Van-Nguyen V, Keppel G et al. A qualitative study of depression in primary care: missed opportunities for diagnosis and education. J Am Board Fam Med 2007; 20: 28-35
• 12 Meltzer H, Bebbington P, Brugha T et al. The reluctance to seek treatment for neurotic disorders. J Mental Health 2000; 9: 319-327
• 13 Martinotti G, Sepede G, Gambi F et al. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder. J Clin Psychopharmacol 2012; 32: 487-491
• 14 Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 2011; 378: 621-631
• 15 Di Giannantonio M, Martinotti G. Anhedonia and major depression: the role of agomelatine. Eur Neuropsychopharmacol 2012; 22: S505-S510
• 16 Aguglia E, Minutolo G, Signorelli MS et al. I bisogni non risolti della depressione maggiore. Giorn Ital Psicopat 2011; 17: 328-334
• 17 Biggio G. Basi neurobiologiche e farmacologiche di una innovativa terapia antidepressiva. Giorn Ital Psicopat 2011; 17: 335-340
• 18 Cuijpers P, Sijbrandij M, Koole SL et al. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry 2014; 13: 56-67
• 19 Thase ME, Greenhouse JB, Frank E et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacology combinations. Arch Gen Psychiatry 1997; 54: 1009-1015
• 20 Angst J, Cui L, Swendsen J et al. Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am J Psychiatry 2010; 167: 1194-1201
• 21 Fava GA, Savron G, Grandi S et al. Cognitive-behavioral management of drug-resistant major depressive disorder. J Clin Psychiatry 1997; 58: 278-282
• 22 Mueller TI, Leon AC, Keller MB et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 1999; 156: 1000-1006
• 23 Andlin-Sobocki P, Wittchen HU. Cost of affective disorders in Europe. Eur J Neurol 2005; 12: 34-38
• 24 Kind P, Sorensen J. The costs of depression. Int Clin Psychopharmacol 1993; 7: 191-195
• 25 Thomas C, Morris S. Cost of depression among adults in England in 2000. Br J Psychiatry 2003; 183: 514-519
• 26 Stoudemire A, Frank R, Hedemark N et al. The economic burden of depression. Gen Hosp Psychiatry 1986; 8: 387-394
• 27 Gustavsson A, Svensson M, Jacobi F et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21: 718-779